Progress of chimeric antigen receptor T cells in the treatment of systemic lupus erythematosus
10.13431/j.cnki.immunol.j.20250085
- VernacularTitle:嵌合抗原受体T淋巴细胞治疗系统性红斑狼疮的研究进展
- Author:
Shuhua WEN
1
;
Tao WANG
;
Meng WEI
Author Information
1. 川北医学院临床医学院,四川南充 637000
- Publication Type:Journal Article
- Keywords:
systemic lupus erythematosus;
chimeric antigen receptor T cell;
chimeric antigen receptor natural killer cells;
rheumatic immune disease
- From:
Immunological Journal
2025;41(8):602-608
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus(SLE)is an autoimmune disease caused by the immune system's abnormal attack on its own tissues.However,traditional anti-rheumatic drugs and biological agents have poor efficacy for some SLE patients and fail to achieve a sustained remission of the disease.Chimeric antigen receptor T lymphocyte(CAR-T)immunotherapy is currently a hot topic in cellular immunotherapy research,bringing new treatment options for SLE patients.CAR-T immunotherapy has shown faster and more durable efficacy in the clinical application of SLE,and is expected to achieve drug-free remission and reduce the occurrence of adverse events.This article expounds the preclinical and clinical research of CAR-T immunotherapy in SLE at present,and reviews the clinical effect,safety and feasibility of clinical application of CAR-T immunotherapy.
